Program
HRS5580
A development code. Also written as “HRS5580 for injection combined with palonosetron hydrochloride;” and “HRS5580 for injection combined with palonosetron hydrochloride”.
In Jiangsu HengRui Medicine's pipeline, NK1
. Its studies are mostly in Vomiting · Postoperative Nausea and Vomiting, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 21 open or running | phase 2since Jun 13, 2024 | Jun 13, 2024 | Dec 2026phase 2 · NCT07709897 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS5580
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 13, 2024First study: phase 2 study in Preventing of Postoperative Nausea and Vomiting in AdultsFirst studyNCT06475846 · 235 enrolled · China
- Jul 8, 2026Phase 2 study in VomitingNCT07709897 · 260 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in VomitingNCT07709897
TargetBeta
“NK1”the company's pipeline, read by Claude · source
Other programs on TACR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aprepitantrule | Merck | phase 4 | 27 |
| elinzanetantrule | Bayer | phase 3 | 24 |
| tradipitantrule | Vanda Pharmaceuticals | phase 3 | 19 |
| fosnetupitantrule | Helsinn Healthcare | phase 3 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07709897Vomiting · China | 2 | Recruiting | Dec 2026 | 260 |
| NCT06475846Preventing of Postoperative Nausea and Vomiting in Adults · China | 2 | Completed | Oct 29, 2024 | 235 |
How it is read
Names in the registry
- “HRS5580”, 3 entries
- “HRS5580 for injection combined with palonosetron hydrochloride;”, 1 entry
- “HRS5580 for injection combined with palonosetron hydrochloride”, 1 entry
Codes read as this program: HRS5580.
Conditions, from the studies’ own filings
- Vomiting, 1 study
- Postoperative Nausea and Vomiting, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.